MedTrace Logo

Hereditary Ataxia Research on Multi-Omics and Neuroclinical Insights in the Yangtze Delta

NCT07092358 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 5000

Last updated 2025-07-29

No results posted yet for this study

Summary

The goal of this observational study is to explore the clinical and genetic characteristics, multi-omics profiles, disease mechanisms, biomarkers, and potential therapeutic targets of hereditary ataxia (HA) in patients diagnosed with HA, primarily in the Yangtze River Delta region of China. The main questions it aims to answer are:

* What are the key pathogenic genetic variants, modifying factors and special inheritance patterns underlying HA?
* How do multi-omics profiles correlate with clinical phenotypes, disease progress and mechanism in HA patients?
* What are the implications of these findings for clinical practice?

Participants will:

* Undergo retrospective and prospective clinical data collection through long-term follow-up to observe disease onset, progression, and outcomes.
* Provide biological samples (e.g., blood, skin) to establish a biobank for multi-omics analyses.
* Be characterized using multidimensional omics technologies to identify disease-related molecular signatures, progression mechanisms, and potential regulatory targets.

Conditions

  • Hereditary Ataxia

Interventions

OTHER

None of intervention

No specific intervention was implemented in this study.

Sponsors & Collaborators

  • Huashan Hospital

    collaborator OTHER

  • Second Affiliated Hospital, School of Medicine, Zhejiang University

    lead OTHER

Principal Investigators

  • Zhi-Ying Wu, M.D&Ph.D · Second Affiliated Hospital of Zhejiang University School of Medicine

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-06-01
Primary Completion
2035-06-30
Completion
2035-12-31

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07092358 on ClinicalTrials.gov